Loading...
Immune checkpoint inhibitors have a modest signal of activity in esophagogastric adenocarcinoma, and pembrolizumab has been approved for treating patients with chemotherapy-refractory PD-L1–positive and microsatellite instability–high-frequency (MSI-high) cancers. However, earlier-line use of pembrolizumab for PD-L1–positive cancers has not been shown to be superior to chemotherapy.
Investigators now report results of the industry-sponsored, international, double-blind, placebo-controlled, randomized, phase III KEYNOTE-062 trial comparing first-line treatment of PD-L1–positive esophagogastric adenocarcinoma with pembrolizumab alone, chemotherapy alone (capecitabine, 5-FU, and cisplatin), or pembrolizumab combined with chemotherapy. Of 763 pa…